Alaska task force debates draft recommendations for psychedelic medical use, sets public comment schedule

A state legislative task force convened by HB 228 discussed draft recommendations Tuesday evening about how Alaska should prepare if psychedelic medicines gain federal approval, and set a timeline for public comment and further drafting.

The group debated whether to finalize a set of recommendations before public testimony and agreed to use a two-step process: a substantive drafting meeting on the committee’s next scheduled date and a public-comment session on Tuesday, April 29. Anna, task force staff lead, summarized the timing options before members: “1 is if we feel like…we could potentially turn around…a draft of recommendations to put out to folks… Another option is that we use…the sixteenth meeting…and then utilize that meeting on Tuesday, April 29 for public comment.”

The task force’s work is framed by the bill that created it, which members repeatedly cited as limiting the group’s scope to recommending how the state should respond if and when federal agencies approve specific therapies. Anna told members the panel’s charge “is set in the…the bill in HB 228,” and that the task force should treat FDA approvals as the likely trigger for detailed implementation planning.

Discussion focused on several recurring issues: who should set clinical standards, how to ensure access across Alaska’s rural and tribal health systems, what credentialing should be required for people who sit with patients during medicine sessions, and how the state should notify the public and gather testimony.

Dr. Lawrence questioned whether the task force should recommend creating a new clinical working group without models to follow, saying she could not find comparable examples and urging caution about prescribing a process the state could not implement unilaterally. Several members recommended relying on the state’s existing Controlled Substances Advisory Committee for regulatory guidance rather than directing creation of new permanent bodies. The task force asked staff to draft language that would reference the Controlled Substances Advisory Committee as the appropriate statutory venue for substance-control recommendations.

On clinical authority, the draft text discussed that prescribing should be limited to providers who already have authorization to prescribe controlled substances and where the treatment falls within their scope of practice. Anna said she had updated the draft to reflect that point.

Members debated whether Alaska should create a training or certification pathway for nonlicensed facilitators who would sit with patients during medicine sessions. Proponents said a nonlicensed pathway could increase access and cultural fit—citing the Community Health Aide Program (CHAP) and community-based organizations (for example, tribal health organizations such as Southcentral Foundation and ANTHC) as models—while others urged state-issued certification or endorsement to provide a clear grievance and enforcement mechanism. Glenn Saviors, speaking for his agency, said he could post public notices through the Department of Commerce but suggested the legislature could also use the statewide online public notice system for official postings.

Members also discussed patient protections: multiple speakers urged written, easily accessible grievance processes and required informed-consent discussions before any medicine session, including explicit, pre-session agreements about touch and boundaries. The task force noted existing statutory grievance procedures for certain involuntary psychiatric settings and asked staff to consider how notice and grievance materials might be standardized for clinics offering these therapies.

On military and veterans’ care, task force members agreed the state should defer to federal processes: whether the U.S. Department of Veterans Affairs (VA) and TRICARE will cover these modalities is a federal question and would determine how the state should advise active-duty and veteran patients.

Procedural votes taken during the meeting included approval of the meeting agenda and approval of minutes from the prior meeting; members recorded no opposition during the live roll calls. The group confirmed quorum early in the session and closed the meeting after staff agreed to redraft recommendations and to circulate updated materials ahead of the next substantive meeting.

The task force instructed staff to: prepare a cleaned-up draft of recommendations (including revised language referencing the Controlled Substances Advisory Committee), circulate PDFs and an editable version to members, coordinate logistics for public testimony (including whether the Legislative Information Office will accept phone testimony), and work with members to distribute notice of the April 29 public comment session. The task force expects to review public testimony in a later meeting and to finalize any formal vote on a report after that input.